DATA, ANALYSIS, AND STRATEGY
Healthcare policy consulting
To help Medicare Advantage plans navigate significant challenges and opportunities in 2026, we offer insight on six developing issues.
After Trump’s executive order calling for most-favored-nation pricing for prescription drugs, we highlight six considerations for life science companies.
Whether you're seeking clarity on the new administration’s direction or a breakdown of the likely policy shifts in healthcare, our team is here to empower your strategy.
In the wake of the FTC’s recent transparency report on pharmacy benefit managers, we look at how reform might impact drug channel stakeholders.
Explore the 2024 Supreme Court rulings on health insurance and retirement benefits regulations, and learn about the end of Chevron deference, new statute of limitations rules, and the requirement for jury trials in civil penalties.
The Centers for Medicare and Medicaid Services (CMS) announced a new total cost of care (TCOC) initiative called States Advancing All-Payer Health Equity Approaches and Development (AHEAD).
We expect the financial implications of the Inflation Reduction Act to lead to a reassessment of formulary strategies by Medicare Part D plans.
Given the medical costs of nonfatal firearm injuries, healthcare stakeholders have an interest in supporting further research to mitigate firearm injury risk.
We describe significant racial disparities in access to preventive diabetes care.